WARFARIN ASPIRIN RECURRENT STROKE STUDY

华法林 阿司匹林 复发性中风研究

• 批准号: 6115308
• 负责人: MARC D WINKELMAN
• 金额: $ 1.92万
• 依托单位: CASE WESTERN RESERVE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6115308
• 关键词: aspirin; brain disorder chemotherapy; cardiovascular disorder chemotherapy; clinical research; clinical trials; human mortality; human subject; human therapy evaluation; relapse /recurrence; stroke; warfarin

An investigator initiated, randomized, double-blind, multi-center, clinical trial designed to test the primary null hypothesis that warfarin therapy will not reduce the frequency of death or ischemic stroke recurrence by 30% compared with aspirin therapy. The trial will also test that the rate of death and recurrent stroke with warfarin will not be 50% lower in one year compared with aspirin therapy; there will be no differences between the two therapies in the frequency of recurrence by stroke severity or subtype, race or sex.

一项研究人员发起了一项随机、双盲、多中心临床试验，旨在检验主要无效假设，即与阿司匹林治疗相比，华法林治疗不会将死亡或缺血性中风复发的频率降低 30%。 该试验还将测试华法林治疗与阿司匹林治疗相比，一年内死亡率和复发性中风的发生率不会降低50%；两种疗法之间的复发频率不会因中风严重程度或亚型、种族或性别而存在差异。